Drugs Made In America Acquisition II Corp. operates as a blank check company. The company is headquartered in Fort Lauderdale, Florida. The company went IPO on 2025-09-25. The firm is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The firm has neither engaged in any operations nor generated any revenue to date.
Drugs Made In America Acquisition II Corp 的关键财务报表是什么?
根据最新的财务报表(Form-10K),Drugs Made In America Acquisition II Corp 的总资产为 $0,净损失为 $0
DMIIU 的关键财务比率是什么?
Drugs Made In America Acquisition II Corp 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Drugs Made In America Acquisition II Corp 的收入按细分市场或地理位置如何划分?
Drugs Made In America Acquisition II Corp 最大收入来源是 Formula One,在最近的收益报告中收入为 3,873,000,000。就地区而言, United Kingdom 是 Drugs Made In America Acquisition II Corp 的主要市场,收入为 3,782,000,000。
Drugs Made In America Acquisition II Corp 是否盈利?
不,根据最新的财务报表,Drugs Made In America Acquisition II Corp 的净损失为 $0
Drugs Made In America Acquisition II Corp 有负债吗?
不,Drugs Made In America Acquisition II Corp 的负债为 0
Drugs Made In America Acquisition II Corp 的流通股有多少?
Drugs Made In America Acquisition II Corp 的总流通股为 0